Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

Phase 3 Trial Initiated To Evaluate Combination Therapy Of Nexavar(R) And Tarceva(R) In Patients With Liver Cancer
Bayer HealthCare LLC., Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Roche today announced the initiation of a Phase 3 trial examining Nexavar(R) (sorafenib) tablets in combination with Tarceva(R) (erlotinib) tablets as a potential new treatment option for patients with advanced hepatocellular carcinoma (HCC), or primary liver cancer.
generic viagra online
Gender Difference In Heart Failure
Striking differences in the risk factors for developing heart failure (HF) and patient prognosis exist between men and women. Men and women may also respond differently to treatment, raising concerns about whether current practices provide the best care and reinforcing the urgency for sex-specific clinical trials for HF, according to a review article published in the August 4, 2009, issue of the Journal of the American College of Cardiology.
News of the day
Medicare Payments Get Attention In House Democrats' Plan
Bloomberg reports that "While the House Democrats" plan would boost Medicare payments to primary-care physicians, it will also cut payments to Medicare Advantage health plans. Details of those cuts weren"t provided." Bloomberg details other features of the legislation: "An outline of the plan also says Democrats drafting the House bill will propose new restrictions on insurers, including caps on out-of-pocket health-care expenses in policies to protect consumers from bankruptcy. The legislation also would bar insurers from excluding people based on pre-existing conditions, according to the outline, a copy of which was obtained by Bloomberg News" (Litvan and Rowley, 6/9).
Nutrition

Hatwig Receives American Society of Health-System Pharmacists Award Of Excellence

The American Society of Health-System Pharmacists (ASHP) today honored Christopher A. Hatwig, M.S., FASHP, with the ASHP Board of Directors Award of Excellence for his work to help safety net hospitals provide safe and cost-effective drug therapy to low-income and uninsured patients. Hatwig, vice president of Apexus in Irving, Texas, received the award during ASHP"s Summer Meeting in Rosemont, Ill. Apexus is responsible for managing the Health Res and Services Administration"s (HRSA) 340B Prime Vendor Program. Mr. Hatwig works closely with HRSA"s Office of Pharmacy Affairs and the Pharmacy Services Support Center in Washington, D.C. to educate all stakeholders, and to improve the integrity and value of the 340B Drug Pricing Program for the nation"s safety-net providers. Under his leadership, the program generated savings of over $24 million or an average savings of 16 percent below the federal 340B ceiling price on its contracted products in 2008. Apexus is a wholly owned non-profit subsidiary of Provista Inc. Before joining Apexus, Hatwig was the director of ambulatory pharmacy services and value analysis programs at Parkland Health & Hospital System in Dallas where he practiced for 13 years. At Parkland he managed one of the nation"s largest and more progressive ambulatory pharmacy programs serving the low-income and uninsured. He was responsible for managing Parkland"s network of ambulatory pharmacies, which processed over two million prescriptions annually and operated with a drug expense budget of $65 million. "Mr. Hatwig"s work with the 340B program ensures that the most vulnerable patients in our country have access to the critical medications that they need and the expertise of pharmacists to guide their use," said Kevin J. Colgan, M.A., FASHP. "We are pleased to recognize his efforts with the Award of Excellence." Hatwig has made numerous presentations on the 340B drug pricing program, innovative ambulatory pharmacy services, and drug cost containment strategies. He has served as chair of the ASHP Council on Administrative Affairs and is a reviewer for the American Journal of Health-System Pharmacy. He is also a member of the Texas Society of Health-System Pharmacists and the Academy of Managed Care Pharmacy. Mr. Hatwig received his bachelor"s degree in pharmacy from the University of Arkansas and completed residencies in hospital pharmacy and hospital pharmacy administration at the University of Wisconsin, where he also received a master"s degree in hospital pharmacy. American Society of Health-System Pharmacists


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009